Skip to Content

Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals

August 8, 2016

DUBLIN, Aug. 8, 2016 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals, effective August 15, 2016.  

"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business," said Rajiv De Silva, President and CEO of Endo. "I look forward to Joe's leadership and contributions to our branded organization and working with him to effectively deliver Endo's innovative therapies to patients with significant unmet need."

"Additionally, I would like to extend my sincere thanks to Brian Lortie for his continued leadership in this role during the transition. We wish Brian much continued success in his future endeavors," added De Silva.

Prior to joining Endo, Mr. Ciaffoni served as Senior Vice President, Global Specialty Medicines Group for Biogen. In this role, he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Mr. Ciaffoni started his employment with Biogen Idec in 2012 and during his tenure held senior roles including Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Previously, he served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni holds a B.A. in Communications and an M.B.A. from Rutgers, The State University of New Jersey.

"I am thrilled to be joining Endo at a time of such significant opportunity for the business," said Mr. Ciaffoni. "I look forward to leading Endo's U.S. branded pharmaceutical business, driving the development and execution of Endo's branded strategy and accelerating key growth drivers while, ultimately, helping improve patients' lives."

About Endo International plc
Endo International plc is a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements," including, but not limited to, the statements by Mr. De Silva and Mr. Ciaffoni. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo's periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval ("SEDAR"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.  Additional information about Endo is available on the World Wide Web at or you can contact the Endo Investor Relations department by calling (484) 216-0000. 

To view the original version on PR Newswire, visit:

SOURCE Endo International plc

Investors/Media: Keri P. Mattox, (484) 216-7912; Media: Heather Zoumas-Lubeski, (484) 216-6829